41 results about "Blood coagulation factor IX" patented technology

The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII / activated blood coagulation factor VIII which enhances the enzymatic reaction.

Various bispecific antibodies that specifically bind to both blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.

The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide or the derivative, wherein the peptide comprises the full-length blood coagulation factor IX, a segment derived from the full-length blood coagulation factor IX by removal of the trypsin domain, the light chain of blood coagulation factor IX, or the EGF1 domain of blood coagulation factor IX, or the EGF3 domain of the endothelial cell locus-1 protein.

An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and / or treated more effectively.

The invention relates to a preparation method of a clinical blood coagulation inspection preparation and particularly relates to a preparation method of a blood coagulation factor IX quality control product. The preparation method comprises the following steps: carrying out affinity chromatography on the mixed blood plasma of multiple persons by using an anti-human blood coagulation factor IX monoclonal antibody immunoaffinity chromatography column, removing a blood coagulation factor IX in the mixed blood plasma of multiple persons to obtain a blood plasma in shortage of the blood coagulation factor IX; mixing the mixed blood plasma of multiple persons with the blood plasma in shortage of the blood coagulation factor IX according to a certain proportion to prepare a blood coagulation factor IX quality control product with the content of the blood coagulation factor IX at different concentration levels, adding a freeze-drying protective additive, carrying out sub-packaging, and carrying out freeze drying so as to obtain the blood coagulation factor IX quality control product. According to the blood coagulation factor IX quality control product prepared by the preparation method, the uniformity, the stability and the stability of freeze-dried aquatic product subjected to re-melting are good, and the quality control product can replace an imported product to be used for quality control on detection of blood coagulation factor IX, so that the reduction of the detection cost is facilitated and the capability of detecting the blood coagulation factor IX in China can be promoted.

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and / or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII can be prevented and / or treated more effectively.

The present inventors verified the coagulation promoting effect of multispecific antigen binding molecules, said molecules replacing the function of FVIII, using blood and plasma collected from patients with FIX abnormality. As a result, it is clarified that a multispecific antigen binding molecule replacing the function of FVIII is not only usable in a method for preventing and / or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand's disease and hemophilia C caused by the dysfunction of FVIII but also usable in a method for preventing and / or treating bleeding in FIX abnormality owing to the coagulation promoting activity thereof. It is also clarified that the effect of a FIX preparation can be enhanced by the combined use of the FIX preparation with the multispecificantigen binding molecule replacing the function of FVIII and this combined use appears promising as a combination therapy showing a stable hemostatic effect.

The invention relates to the field of medicinal biotechnology, and in particular to a high-purity prothrombin complex product stabilizer capable of effectively preventing the inactivation of a blood coagulation factor IX with a main effect and blood coagulation factors II, VII and X in a product in a freeze-drying process, wherein the specific activity of each of four blood coagulation factors II, VII, IX and X is greater than or equal to 3.5IU / mg protein. The stabilizer provided by the invention contains arginine or / and trehalose or / and histidine or / and glycine. The tests show that so long as the high-purity prothrombin complex contains 0.1-10% of arginine or / and 0.1-10% of trehalose or / and 0.1-10% of histidine, the activity of the blood coagulation factor IX and the activity of the blood coagulation factors II, VII and X can be effectively protected in the freeze-drying process. Thus, the stabilizer provided by the invention can be applied to the freeze-drying process of the high-purity prothrombin complex.